FY2019 Earnings Forecast for Mirati Therapeutics Inc Issued By Jefferies Financial Group (NASDAQ:MRTX)

Mirati Therapeutics Inc (NASDAQ:MRTX) – Equities researchers at Jefferies Financial Group cut their FY2019 earnings per share (EPS) estimates for shares of Mirati Therapeutics in a research note issued to investors on Tuesday, November 5th. Jefferies Financial Group analyst M. Raycroft now forecasts that the biotechnology company will post earnings of ($5.18) per share for the year, down from their previous forecast of ($4.90). Jefferies Financial Group currently has a “Buy” rating and a $105.00 target price on the stock. Jefferies Financial Group also issued estimates for Mirati Therapeutics’ Q4 2019 earnings at ($1.35) EPS, FY2020 earnings at ($4.96) EPS, FY2021 earnings at ($5.21) EPS and FY2022 earnings at ($2.84) EPS.

Mirati Therapeutics (NASDAQ:MRTX) last issued its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($1.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.25) by ($0.13). The company had revenue of $0.99 million for the quarter, compared to the consensus estimate of $0.50 million. Mirati Therapeutics had a negative return on equity of 48.60% and a negative net margin of 2,698.66%.

Other research analysts have also issued research reports about the company. Cowen reiterated a “buy” rating on shares of Mirati Therapeutics in a research report on Friday, October 18th. Leerink Swann set a $118.00 price target on Mirati Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Citigroup set a $130.00 price target on Mirati Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Credit Suisse Group set a $115.00 price target on Mirati Therapeutics and gave the stock a “buy” rating in a research report on Friday, September 27th. Finally, ValuEngine upgraded Mirati Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $105.67.

MRTX stock traded up $1.15 during trading on Friday, reaching $99.15. 2,082 shares of the company’s stock were exchanged, compared to its average volume of 904,291. Mirati Therapeutics has a 1-year low of $34.39 and a 1-year high of $111.99. The company’s fifty day moving average price is $83.68 and its 200-day moving average price is $86.98. The firm has a market cap of $3.86 billion, a PE ratio of -30.72 and a beta of 2.05.

Institutional investors have recently made changes to their positions in the company. Aperio Group LLC acquired a new stake in shares of Mirati Therapeutics in the second quarter valued at $50,000. NumerixS Investment Technologies Inc purchased a new stake in shares of Mirati Therapeutics during the second quarter valued at $52,000. Quantamental Technologies LLC purchased a new stake in shares of Mirati Therapeutics during the second quarter valued at $59,000. First Mercantile Trust Co. purchased a new stake in shares of Mirati Therapeutics during the second quarter valued at $89,000. Finally, Tower Research Capital LLC TRC purchased a new stake in shares of Mirati Therapeutics during the third quarter valued at $112,000.

In other news, Director Michael G. Grey sold 3,042 shares of the company’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $92.27, for a total value of $280,685.34. Following the completion of the sale, the director now owns 4,840 shares in the company, valued at $446,586.80. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Bruce L. A. Carter sold 3,000 shares of the company’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $89.24, for a total value of $267,720.00. Following the completion of the sale, the director now owns 3,000 shares of the company’s stock, valued at approximately $267,720. The disclosure for this sale can be found here. In the last 90 days, insiders sold 57,852 shares of company stock valued at $5,015,464. Insiders own 4.86% of the company’s stock.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.

Featured Article: How do CD ladders protect against rising interest rates?

Earnings History and Estimates for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit